PFE - Taysha Gene Therapies Seeks $125 Million IPO For Ambitious Pipeline
Quick Take
Taysha Gene Therapies (TSHA) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement.
The company is developing genetic therapy treatments for various neurodegenerative diseases and other disorders.
TSHA is still at a preclinical stage and the IPO is priced above the typical range for clinical stage biopharma IPOs, so it may be more suited to long-term hold institutional investors.
Company & Technology
Dallas, Texas-based Taysha was founded to advance its pipeline of various gene AAV (adeno-associated virus delivered) therapy candidates